LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Fermé

SecteurSoins de santé

0.73 -3.95

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.72

Max

0.76

Chiffres clés

By Trading Economics

Revenu

1.1M

-1.2M

Ventes

141K

21M

Marge bénéficiaire

-5.978

Employés

330

EBITDA

1M

1.2M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+163.16% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.2M

34M

Ouverture précédente

4.68

Clôture précédente

0.73

Sentiment de l'Actualité

By Acuity

26%

74%

84 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Harvard Bioscience Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 déc. 2025, 22:02 UTC

Résultats

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 déc. 2025, 21:46 UTC

Résultats

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 déc. 2025, 23:52 UTC

Acquisitions, Fusions, Rachats

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 déc. 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 déc. 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 déc. 2025, 23:20 UTC

Résultats

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 déc. 2025, 23:15 UTC

Résultats

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 déc. 2025, 22:59 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 déc. 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 déc. 2025, 22:40 UTC

Résultats

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 déc. 2025, 22:06 UTC

Acquisitions, Fusions, Rachats

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 déc. 2025, 22:06 UTC

Résultats

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 déc. 2025, 22:02 UTC

Résultats

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 déc. 2025, 22:00 UTC

Résultats

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 déc. 2025, 21:53 UTC

Résultats

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 déc. 2025, 21:50 UTC

Acquisitions, Fusions, Rachats

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 déc. 2025, 21:50 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

10 déc. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 déc. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 déc. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 déc. 2025, 21:33 UTC

Résultats

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 déc. 2025, 21:32 UTC

Résultats

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 déc. 2025, 21:28 UTC

Acquisitions, Fusions, Rachats

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 déc. 2025, 21:25 UTC

Résultats

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 déc. 2025, 21:18 UTC

Acquisitions, Fusions, Rachats

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 déc. 2025, 21:16 UTC

Résultats

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 déc. 2025, 21:15 UTC

Acquisitions, Fusions, Rachats

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 déc. 2025, 21:15 UTC

Résultats

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 déc. 2025, 21:14 UTC

Résultats

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 déc. 2025, 21:14 UTC

Résultats

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparaison

Variation de prix

Harvard Bioscience Inc prévision

Objectif de Prix

By TipRanks

163.16% hausse

Prévisions sur 12 Mois

Moyen 2 USD  163.16%

Haut 2 USD

Bas 2 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.3 / 0.3401Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

No Evidence

Long Terme

No Evidence

Sentiment

By Acuity

84 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat